KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization (CF) (2016 - 2025)

TherapeuticsMD's Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $97000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 3.0% year-over-year to $97000.0; the TTM value through Dec 2025 reached $384000.0, down 24.56%, while the annual FY2025 figure was $384000.0, 24.56% down from the prior year.
  • Depreciation & Amortization (CF) reached $97000.0 in Q4 2025 per TXMD's latest filing, up from $96000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.0 million in Q2 2021 to a low of -$2.4 million in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $187250.0, with a median of $131500.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): tumbled 329.09% in 2021, then soared 392.59% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at -$2.4 million in 2021, then soared by 113.12% to $309000.0 in 2022, then surged by 106.15% to $637000.0 in 2023, then plummeted by 84.3% to $100000.0 in 2024, then decreased by 3.0% to $97000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Depreciation & Amortization (CF) are $97000.0 (Q4 2025), $96000.0 (Q3 2025), and $96000.0 (Q2 2025).